China Becomes the First in the World to Approve Commercial Use of a Neurochip, Ahead of Elon Musk's Neuralink

{
  "signal_id": "54c9745d-c250-1b25-7767-300e10711927",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-22T17:30:00+00:00",
  "company": {
    "name": "Neuralink",
    "domain": "neuralink.com"
  },
  "data": {
    "url": "https://sud.ua/en/news/abroad/372924-kytai-pershym-u-sviti-dozvolyv-komertsiine-vykorystannia-neirochypa-vyperedyvshy-neuralink-ilona-maska",
    "title": "China Becomes the First in the World to Approve Commercial Use of a Neurochip, Ahead of Elon Musk's Neuralink - Судово-юридична газета",
    "excerpt": "China has overtaken the US in the neurointerface race. On March 13, 2026, the National Medical Products Administration of China (NMPA) issued the world’s first permit for the commercial use of an implanted brain-computer interface (BCI). Only the latest: read SUD.UA on Telegram The NEO device, developed by Neuracle, also known as Borui Kang Medical Technology, in collaboration with Tsinghua University, was registered as a Class III medical device, allowing its free sale and use outside clinical trials. First Commercial Operation At Huashan Hospital (Shanghai, Fudan University) on July 13, 2026, neurosurgeons performed the first commercial implantation of NEO. The patient was a man with quadriplegia caused by a cervical spinal cord injury. After the operation, he was able to control a special robotic glove with his mind, regaining the ability to grasp objects. What the Chinese Neurointerface Enables NEO is intended for patients aged 18–60 with paralysis of all four limbs due to cervical injuries (C2–C6). The system consists of: Clinical trials involving 32 patients across 11 hospitals showed a 100% success rate in achieving the endpoint - controlled object grasping. Neuralink: Clinical Trials Ongoing In contrast to China, Elon Musk’s Neuralink had not received FDA approval for commercial sales as of September 2026. According to Reuters, as of January 28, 2026, 21 people...",
    "product": "neurointerface",
    "summary": "Elon Musk's Neuralink is conducting clinical trials for its neurointerface technology in the US, Canada, UAE, and the UK, but had not received FDA approval for commercial sales as of September 2026.",
    "planning": false,
    "image_url": "https://sud.ua/uploads/news/2026/09/22/kytai-pershym-u-sviti-dozvolyv-komertsiine-vykorystannia-neirochypa-vyperedyvshy-neuralink-ilona-maska.webp",
    "confidence": 0.8,
    "product_data": {
      "name": "neurointerface",
      "full_text": "neurointerface",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "future_tech",
      "medical"
    ],
    "published_at": "2026-09-22T17:30:00Z",
    "article_sentence": "In contrast to China, Elon Musk’s Neuralink had not received FDA approval for commercial sales as of September 2026."
  }
}

curl https://signals.autobound.ai/v1/signals/54c9745d-c250-1b25-7767-300e10711927 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"neuralink.com","limit":20}'